➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Merck
Colorcon
Boehringer Ingelheim
Mallinckrodt

Last Updated: October 22, 2021

DrugPatentWatch Database Preview

Casimersen - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic drug sources for casimersen and what is the scope of patent protection?

Casimersen is the generic ingredient in one branded drug marketed by Sarepta Theraps Inc and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Casimersen has one hundred and sixty-nine patent family members in twenty-three countries.

One supplier is listed for this compound.

Summary for casimersen
International Patents:169
US Patents:8
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 2
What excipients (inactive ingredients) are in casimersen?casimersen excipients list
DailyMed Link:casimersen at DailyMed
Recent Clinical Trials for casimersen

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Kevin FlaniganPhase 2
Sarepta Therapeutics, Inc.Phase 2
Sarepta TherapeuticsPhase 3

See all casimersen clinical trials

Pharmacology for casimersen

US Patents and Regulatory Information for casimersen

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sarepta Theraps Inc AMONDYS 45 casimersen SOLUTION;INTRAVENOUS 213026-001 Feb 25, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Sarepta Theraps Inc AMONDYS 45 casimersen SOLUTION;INTRAVENOUS 213026-001 Feb 25, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Sarepta Theraps Inc AMONDYS 45 casimersen SOLUTION;INTRAVENOUS 213026-001 Feb 25, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Sarepta Theraps Inc AMONDYS 45 casimersen SOLUTION;INTRAVENOUS 213026-001 Feb 25, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Sarepta Theraps Inc AMONDYS 45 casimersen SOLUTION;INTRAVENOUS 213026-001 Feb 25, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Sarepta Theraps Inc AMONDYS 45 casimersen SOLUTION;INTRAVENOUS 213026-001 Feb 25, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Sarepta Theraps Inc AMONDYS 45 casimersen SOLUTION;INTRAVENOUS 213026-001 Feb 25, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for casimersen

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sarepta Theraps Inc AMONDYS 45 casimersen SOLUTION;INTRAVENOUS 213026-001 Feb 25, 2021 ⤷  Free Forever Trial ⤷  Free Forever Trial
Sarepta Theraps Inc AMONDYS 45 casimersen SOLUTION;INTRAVENOUS 213026-001 Feb 25, 2021 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for casimersen

Country Patent Number Estimated Expiration
South Korea 101958491 ⤷  Free Forever Trial
European Patent Office 1766012 ⤷  Free Forever Trial
Austria 498685 ⤷  Free Forever Trial
European Patent Office 2305200 ⤷  Free Forever Trial
European Patent Office 3228711 ⤷  Free Forever Trial
Japan 5963678 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 2010054267 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Merck
Colorcon
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.